Rare Immunology News
Advertisement
Spotlight On
CTLA-4 Haploinsufficiency
CTLA-4 haploinsufficiency is a genetic disorder caused by a mutation in one copy of the CTLA-4 gene, leading to reduced CTLA-4 protein production. This results in a range of immune dysregulation issues, including autoimmunity, lymphoproliferation, and immunodeficiency
Prevalence
2/100,000
150–400
US Estimated
200–600
Europe Estimated
Age of Onset
All ages
ICD-10
D89.8
Inheritance
Autosomal dominant
Autosomal recessive
Mitochondrial/Multigenic
X-linked dominant
X-linked recessive
5 Facts you should know
FACT
CTLA-4 haploinsufficiency leads to a breakdown in immune tolerance, causing lymphoproliferation and multiple autoimmune manifestations, including cytopenias and enteropathy
FACT
Not all individuals with CTLA-4 mutations develop symptoms; affected members of the same family may exhibit very different clinical presentations
FACT
These are frequent findings, often accompanied by recurrent infections due to impaired immune regulation
FACT
This CTLA-4-Ig fusion protein can help manage autoimmunity by mimicking the regulatory function of CTLA-4
FACT
Early molecular diagnosis enables timely immunologic monitoring, family screening, and potential disease-modifying interventions
Interest over time
Google searches
Common signs and symptoms
Recurrent infections
Autoimmune diseases
Lymphoproliferation
Hypogammaglobulinemia
Interstitial lung disease
Neurological involvement
Current treatments
Immunoglobulin replacement therapy
IVIG or SCIG
Immunosuppressive therapy
corticosteroids, sirolimus
Targeted therapy with Abatacept
CTLA-4 fusion protein
Hematopoietic stem cell transplantation (HSCT)
in severe or progressive cases